Presentazione workshop sies 2015 muccio
•
1 like•141 views
Flow cytometry is an useful tool to study hematological diseases at diagnosis and after treatment. We study new plasma cells' surface antigens to improve the minimal residual disease study in multiple myeloma. Some of new antigens studied are very helpful after immunotherapy with monoclonal antibodies.
Recommended
More Related Content
Recently uploaded
Recently uploaded (20)
Featured
Featured (20)
Presentazione workshop sies 2015 muccio
- 1. SUITABLE SURFACE ANTIGENS FOR MYELOMA AND NORMAL PLASMA CELLS IDENTIFICATION AFTER MONOCLONAL ANTIBODIES THERAPY. Vittorio Emanuele Muccio Divisione Universitaria di Ematologia Prof. M. Boccadoro A.O.U Città della Salute e della Scienza di Torino Vittorio Emanuele Muccio
- 3. Surface markers to identify PCs Surface markers to identify MALIGNANT Cs PLASMA CELLS AND FLOW CYTOMETRY Vittorio Emanuele Muccio
- 4. CD38 why? CD138 why? CD40 B lymphocytes and Antigen-Presenting Cells CD31 Platelets, monocytes, neutrophils and T lymphocytes Surface markers to identify PCs Vittorio Emanuele Muccio
- 5. CD117 CD13 CD14CD15 CD20 CD10 CD27 CD19 CD9 CD11bCD40 CD31 CD41 CD56 CD45 CD28 CD23 CD22 CD33 CD24 CD25 CD37 CD39 CD71 HLA-DR CD44 CD4 CD8 CD81 CD38 CD200 Surface markers to identify malignant PCs Vittorio Emanuele Muccio
- 6. EuroFlow panel for MM MRD study Tube 1 CD138 CD27 CD38 CD56 CD45 CD19 CD117 CD81 Tube 2 CD138 CD27 CD38 CD56 CD45 CD19 cyIgKappa cyIgLambda Vittorio Emanuele Muccio
- 7. Immunotherapies in MM Anti-CD38 Anti-CD138 Anti-CD56 Anti-CD319 Anti-CD40 Vittorio Emanuele Muccio
- 8. EuroFlow panel for MM MRD study Tube 1: CD138 CD27 CD38 CD56 CD45 CD19 CD117 CD81 Tube 2: CD138 CD27 CD38 CD56 CD45 CD19 cyIgKappa cyIgLambda Vittorio Emanuele Muccio
- 9. 9th International Conference on Human Leukocyte Differentiation Antigens (HLDA9) 82 Surface molecules SIALOADESINES SLAM INTEGRINSTNF/TNFR IRTA CITOCHINES-R CHEMOKINES-R CD28/B7TLR/C-TYPE LEC R Vittorio Emanuele Muccio
- 10. # mAb Specificity Conjugated fluorochrome CD Isotype Ab Species % of positive MM samples 20 FCRL1 PE CD307a IgG1k Mouse 0 21 FCRL2 PE CD307b IgG2Ak Mouse 0 22 FCRL3 PE CD307c IgG2Bk Mouse 0 23 FCRL4 PE CD307d IgG2Ak Mouse 0 28 Siglec-7 PE CD328 IgG1k Mouse 0 29 B7-2 PE CD86 IgG1k Mouse 64* 30 IL-10R PE CD210 IgG2ak Rat 0 31 CCR7 PE CD197 IgG2ak Rat 0 32 Siglec-9 PE CDw329 IgG1k Mouse 0 33 HB15 PE CD83 IgG1k Mouse 0 34 CTLA-4 PE CD152 IgG2ak Mouse 0 35 B7-1 PE CD80 IgG1k Mouse 0 36 IL6-Rα PE CD126 IgG1k Mouse 45 37 PD1 PE CD279 IgG1k Mouse 0 38 B7-DC PE CD273 IgG1k Mouse 0 39 IL-4Rα PE CD124 IgG1k Mouse 0 40 OX2 PE CD200 IgG1k Mouse 70* 41 gp130 PE CD130 IgG1k Mouse 45 42 IL-12R PE CD212 IgG1k Mouse 0 43 Siglec PE CD328 IgG1k Mouse 0 44 CCR2 A647 CD192 IgG2b Mouse 18 45 ICOS PE CD278 IgG1 Mouse 0 46 CXCR4 PE CD184 IgG2ak Mouse 64* 47 BTLA PE CD272 IgG1k Mouse 64* 48 CCR6 PE CD196 IgG1k Mouse 18 49 TACI PE CD267 IgG2ak Rat 0 50 CXCR5 A647 CD185 IgG2bk Rat 45 51 Integrin beta 7 chain PE NONE IgG2ak Rat 0 52 CCR1 A647 CD191 IgG2bk Mouse 27 53 Integrin beta 5 PE NONE IgG1 k Mouse 0 54 B7-H4 PE NONE IgG1 k Mouse 0 55 DR4 PE CD271 IgG1 k Mouse 0 56 CMKLR1 PE NONE IgG2a k Rat 0 57 DR5 PE CD262 IgG1 k Mouse 18 74 Integrin beta 6 PE NONE IgG2b Mouse 0 75 Dectin-1/CLEC7A PE NONE IgG2b Mouse 0 76 TREM-1 PE NONE IgG1 Mouse 10 77 Siglec-5/Siglec-14 APC CD170 IgG1 Mouse 0 78 AMICA PE NONE IgG2a Mouse 0 79 BLT1/LTB4R1 PE NONE IgG1 Mouse 10 80 Siglec-9 APC CD329 IgG2a Mouse 0 81 IL-23-R PE NONE IgG2b Mouse 9 82 Integrin alfaVbeta5 PE NONE IgG1 Mouse 0 83 CRTAM PE CD355 IgG2b Mouse 0 84 DCIR/CLEC4A PE NONE IgG1 Mouse 0 85 GITR PE NONE IgG1k Mouse 0 86 Ly9 PE CD229 IgG1k Mouse 100* 87 CRACC PE CD319 IgG2b k Mouse 100* 88 BLAST-1 PE CD48 IgG1k Mouse 100* 89 SLAMF5 PE CD84 IgG2a k Mouse 17 90 Toll-like Receptor 3 PE CD283 IgG2a k Mouse 0 91 DcR3 PE NONE IgG1k Mouse 9 92 DR3 (TRAMP) PE NONE IgG1k Mouse 0 93 NTBA PE NONE IgG1k Mouse 100* 94 HVEM PE CD270 IgG1k Mouse 45 95 TSLPR PE NONE IgG1k Mouse 0 96 TWEAK PE CD255 IgG3 k Mouse 0 97 TCL1 PE NONE IgG2b k Mouse 0 98 Galectin-3 (Mac-2) PE NONE IgG1k Mouse 0 99 GITR-L PE NONE IgG1k Mouse 0 100 Lymphotoxin beta receptor PE NONE IgG2b k Mouse 0 101 TREM-1 PE NONE IgG1k Mouse 0 106 SLAM PE CD150 IgG1k Mouse 67* 109 S1PR1 PE CD363 IgG2B Mouse 0 234 IL-15Ralfa PE NONE IgG2b k Mouse 0 235 BAFF-R PE CD268 IgG1 k Mouse 20 236 LIGHT PE CD258 IgG2b k Mouse 20 237 BAFF PE CD257 IgG1 k Mouse 40 238 CD274 PE CD274 IgG2b k Mouse 45 239 B7-H2 PE CD275 IgG2b k Mouse 20 240 CD267 PE CD267 IgG2a k Rat 20 241 NKG2D PE CD314 IgG1 Mouse 0 242 LAIR1 PE CD305 IgG2b Mouse 0 243 DEP-1 PE CD148 IgG1 Mouse 20 244 Syndecan-2 PE NONE IgG2b Rat 20 245 CXCR7/RDC-1 PE NONE IgG2a Mouse 0 246 IL21R PE NONE IgG1 Mouse 0 247 Toll-like Receptor 9 PE CD289 IgG2a k Rat 0 249 TACI PE CD267 IgG2a Mouse 40 250 ABCG2 PE CDw338 IgG2b k Mouse 0 251 BR3 PE CD268 IgG2a k Mouse 0 252 BLyS PE CD257 IgG1 k Mouse 0 In the right column the percentage of positive samples at diagnosis of MM is reported. Only antigens expressed in >50% of patients were selected for the second phase of the study, # mAb Specificity Conjugated fluorochrome CD Isotype Ab Species % of positive MM samples 29 B7-2 PE CD86 IgG1k Mouse 64* 40 OX2 PE CD200 IgG1k Mouse 70* 46 CXCR4 PE CD184 IgG2ak Mouse 64* 47 BTLA PE CD272 IgG1k Mouse 64* 86 Ly9 PE CD229 IgG1k Mouse 100* 87 CRACC PE CD319 IgG2b k Mouse 100* 88 BLAST-1 PE CD48 IgG1k Mouse 100* 93 NTBA PE NONE IgG1k Mouse 100* 106 SLAM PE CD150 IgG1k Mouse 67* TESTED ANTIBODIES Vittorio Emanuele Muccio
- 11. 35 NEWLY DIAGNOSED MM 15 HEALTHY SUBJECTS CD86 CD200 CD272 CD184 CD229 CD319 CD352 CD150 CD48 SECOND PHASE OF THE STUDY Vittorio Emanuele Muccio
- 12. PERCENTAGES OF POSITIVE PCs * * * ** * * * Vittorio Emanuele Muccio
- 13. MFI OF POSITIVE PCs * * * * Vittorio Emanuele Muccio
- 14. CONCLUSIONS CD150, CD86, CD200 and CD352 allow the differentiation between healthy and tumor PCs Useful in the MRD study after therapy with Lorvotuzumab (anti-CD56), Dacetuzumab or Lucatumumab (anti-CD40) CD352 Vittorio Emanuele Muccio
- 15. Therapeutic targets? CD272, CD319, CD229 e CD48 are highly expressed by PCs CONCLUSIONS Lymphocytes Monocytes Granulocytes CD150 + + +- - - - - - - CD352 ++ ++ ++ - - - - - - CD86 - - - + + + - - - CD319 -+ -+ -+ - - - - - - CD272 + + + - - - - - - CD184 + + + - - - - - - CD48 + + + + + + - - - CD229 - - - - - - - - - CD200 - - - - - - - - - Vittorio Emanuele Muccio
- 16. Useful to carachterize PCs in the MRD study after therapy with BT062 (anti- CD138) or Daratumumab (anti-CD38) CONCLUSIONS Vittorio Emanuele Muccio
- 17. A.O.U Città della Salute e della Scienza di Torino Divisione Universitaria di Ematologia Prof. M. Boccadoro Dott.ssa Paola Omedè Gilestro Milena Saraci Elona Astolfi Monica Oddolo Daniela Caltagirone Simona Ruggeri Marina Marzanati Eleonora Aschero Simona Gattei Valter Zucchetto Antonella Vittorio Emanuele Muccio